目的 研究竹瀝膠囊聯(lián)合雙黃連注射液治療急慢性咽喉炎的臨床療效。方法 選取2015年1月—2016年12月在湖北醫(yī)藥學(xué)院附屬東風(fēng)醫(yī)院就治的急慢性咽喉炎患者78例，隨機分為對照組和治療組，每組各39例。對照組患者靜脈注射雙黃連注射液，10～20 mL/次，1～2次/d。治療組患者在對照組的基礎(chǔ)上口服竹瀝膠囊，4粒/次，3次/d。兩組患者連續(xù)治療14 d。評價治療后兩組患者臨床療效，同時比較治療前后兩組癥狀消失時間、血清IL-1、IL-6和TNF-α水平、咽炎癥狀評分以及不良反應(yīng)和復(fù)發(fā)率改善情況。結(jié)果 治療后，對照組總有效率為74.36%，顯著低于治療組的92.31%，兩組比較差異具有統(tǒng)計學(xué)意義（P< 0.05）。治療后，治療組患者咽喉干癢、咽喉疼痛、黏膜充血及聲音嘶啞消失時間均顯著短于對照組患者，兩組比較差異具有統(tǒng)計學(xué)意義（P< 0.05）。治療后，治療組患者血清IL-1、IL-6及TNF-α水平均顯著下降（P< 0.05），且治療后治療組患者IL-1、IL-6和腫瘤壞死因子-α（TNF-α）水平明顯低于對照組（P< 0.05）。治療后，兩組患者的咽炎癥狀積分均比治療前有顯著下降（P< 0.05）；且治療組患者評分明顯低于對照組（P< 0.05）。治療后隨訪發(fā)現(xiàn)，治療組患者的不良反應(yīng)發(fā)生率和復(fù)發(fā)率分別為7.69%、2.56%，均顯著低于對照組患者的17.95%、10.26%，兩組比較差異具有統(tǒng)計學(xué)意義（P< 0.05）。結(jié)論 竹瀝膠囊聯(lián)合雙黃連注射液治療急慢性咽喉炎療效優(yōu)于單用雙黃連注射液治療，具有一定的臨床推廣應(yīng)用價值。

Objective To study the therapeutic effect of Zhuli Capsules combined with Shuanghuanglian Injection in treatment of acute and chronic pharyngitis. Methods Patients (78 cases) with acute and chronic pharyngitis in Dongfeng Hospital Affiliated to Hubei Medical College from January 2015 to December 2016 were randomly divided into control and treatment groups, and each group had 39 cases. Patients in the control group were iv administered with Shuanghuanglian Injection, 10-20 mL/time, once to twice daily. Patients in the treatment group were po administered with Zhuli Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, clinical efficacy was evaluated, the improvement of pharyngitis symptom score, symptom disappearance time and serum IL-1, IL-6 and TNF-α levels, adverse reactions and recurrence rates in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 74.36%, which was significantly lower than 92.31% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the clinical symptom disappearance time of throat itching, sore throat, mucosal hyperemia and hoarseness in the treatment group was significantly shorter than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the IL-1, IL-6, and TNF-α levels in two groups were significantly decreased (P < 0.05). And the IL-1, IL-6, and TNF-α levels in the treatment group were significantly lower than that in the control group (P < 0.05). After treatment, the pharyngitis symptom score in two groups were significantly decreased (P < 0.05). And the pharyngitis symptom score in the treatment group were significantly lower than that in the control group (P < 0.05). Follow-up after treatment, adverse reactions incidence and recurrence rate in the control group was 17.95% and 10.26%, which were significantly higher than 7.69% and 2.56% in the treatment group, respectively, and there were differences between two groups (P < 0.05). Conclusion Zhuli Capsules combined with Shuanghuanglian Injection is superior to Shuanghuanglian Injection alone in treatment of acute and chronic pharyngitis, which has a certain clinical application value.